{"disease":{"id":"bone-infections","name":"Bone infections","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":1,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cefoxitin","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cephalexin","indication_name":"Bone infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."},{"drug_id":"cefoxitin-sodium","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"ceftazidime","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"chembl-chembl3989564","indication_name":"Skin, Bone, and Skin Structure Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TOBRAMYCIN SULFATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"cefuroxime-sodium","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"cephalexin","indication_name":"Bone infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEPHALEXIN","company_name":"","drug_phase":"marketed","molecular_target":"Penicillin-binding proteins (PBPs)","drug_class":"First-generation cephalosporin","quality_score":80,"revenue":null,"mechanism":"Cephalexin is a cephalosporin antibacterial drug."}],"pipeline":[],"offLabel":[],"totalMarketed":7,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06418048","title":"INfectious DIsease REgistry BIObank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT03627000","title":"Microbiological Epidemiology in Patients Experiencing Microbiological or Clinical Failure Following Reimplantation After a 2-stage Exchange Strategy for Hip or Knee Prosthetic Joint Infection","phase":"","overall_status":"COMPLETED","enrollment_count":114,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04328051","title":"Influence of the Implant-prosthetic Connection in the Marginal Bone Loss and Bacterial Leakage","phase":"NA","overall_status":"UNKNOWN","enrollment_count":105,"lead_sponsor_name":"University of Barcelona","has_results":false},{"nct_id":"NCT05113303","title":"COREV 2.0 PMCF-Study on Manual and Navigated Revision Knee Patients","phase":"","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Aesculap AG","has_results":false},{"nct_id":"NCT03950063","title":"Cutibacterium Acnes in Bone and Joint Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":50,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT01502072","title":"Respiratory Syncytial Virus - RSV Protocol","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05770856","title":"Clinical Metagenomic of Post-traumatic Infections","phase":"","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer","has_results":false}],"total":7},"guidelines":[],"source":"Drug Landscape verified database"}